This paper was published today (academic access) by researchers(not this time by Dr. Grinspoon and colleagues) covers a comprehensive overview of GHRH/its analogous and their health benefits such as interventions of various serious common diseases. Endogenous GHRH has a short half-life and will be degraded by proteolytic enzymes however Tesamorelin is resistant to proteolysis with longer half life and longer/higher concentration of the drug before breaking down by enzymes. Tesamorelin also decreases the cholesterol levels as excessive levels of cholesterol can clog arteries with increased risks of heart disease ms and stroke.They do also mention the therapeutic benefits of the drug for NAFLD and cognitive disabilities including Alzheimer.
Overall a good coverage of the therapeutic effects of GHRH and it's analogous with multiple references to Tesamorelin by a group of researchers this time not the familiar names!
"Tesamorelin is a different agonistic analogue of GHRH, based on the modification of GHRH(1–44)NH2 with a hexenoyl moiety attached to the tyrosine residue at the N terminus36. Tesamorelin, which is resistant to proteolytic degradation and markedly increases levels of GH and IGF1 (ref. 36), was approved in 2010 by the FDA for the treatment of visceral adiposity in individuals with accumulation of abdominal adipose tissue that is associated with HIV infection.
Lipid disorders
Dyslipidaemia, characterized by abnormal levels of lipids in the blood, is a major risk factor for atherosclerotic cardiovascular disease88. The GHRH agonist tesamorelin was found to decrease serum levels of total cholesterol and low-density lipoprotein in individuals with T2DM.
On the other hand, individuals with obesity and HIV who were treated with the GHRH agonist tesamorelin showed reduced abdominal adiposity and HIV-associated non-alcoholic fatty liver disease (NAFLD) (also known as metabolic dysfunction-associated steatotic liver disease), which suggests that tesamorelin treatment has clinical benefits in liver diseases and on cardiovascular risk.
Subsequently, a controlled trial demonstrated that 5-month subcutaneous administration of tesamorelin attenuated cognitive decline in individuals with impaired cognitive function and in healthy adults aged 55–87 years, with a mean age of 68 years120. Tesamorelin also increased the levels of the inhibitory neurotransmitters γ-aminobutyric acid (GABA) and N-acetylaspartylglutamate, while reducing levels of myo-inositol121, an osmolyte linked to Alzheimer disease in humans."
Growth hormone-releasing hormone and its analogues in health and disease | Nature Reviews Endocrinology